




3rd ICPO FORUM for Theranostics in Precision Oncology

12.-13. October 2023 · Garching Munich, Germany



PROGRAM

Subject to change | Revision June 09, 2023 | All stated times correspond to CENTRAL EUROPEAN TIME

THURSDAY, 12 October 2023

Collaborative efforts to greater patient access to Radio Theranostics

07:30 – 08:30	Registration and Coffee
08:30 – 08:45	Welcome addresses

SESSION I: Keynote lectures

08:45 – 09:05	Importance of real-world evidence for Radiomolecular Theranostics patients Andrew M. Scott, Australia
09:05 – 09:25	Radiomolecular Theranostics amongst Precision Oncology options Oliver Sartor, USA
09:25 - 09:45	PSMA, A game changer for Radiomolecular Theranostics Matthias Eiber, Germany
09:45 – 10:05	Radiomolecular Theranostics: Future perspectives Richard P. Baum, Germany

SESSION II: A break-through in Education: ICPO Academy for Theranostics

10:05 – 10:20	Professional e-learning curriculum: objectives, content and audit/certification Elcin Zan, USA
10:20 – 10:35	Feedback from young clinicians Ishita Sen, India and Jingjing Zhan, Singapore
PANEL 10:35 – 11:05	How certified education improves patient access to Theranostics Moderated by Francesco Giammarile, Austria and Gopinah Gnanasegaran, UK
11:05 – 11:35	Coffee Break (served in exhibition)



THURSDAY, 12 October 2023

Collaborative efforts to greater patient access to Radio Theranostics

Session III: Greater patient access thanks to certified Centers initiatives

11:35 – 11:45	ENETS Centers of Excellence Nicola Fazio, Italy
11:45 – 11:55	ICPO Centers of Excellence Rodney Hicks, Australia
11:55 – 12:05	SNMMI Centers of Excellence Andrei Iagaru, USA
12:05 – 12:15	EANM Centers of Excellence Paola Erba, Italy
12:15 – 12:25	Theranostics research across 3 continents Nat Lenzo, Australia
PANEL 12:25 – 12:55	How Centers of Excellence improve patient access to Theranostics Moderated by Richard P. Baum, Germany and N.N.

Industry Lunch Symposium 13:15 – 13:45 / **Lunch** served in exhibition 12:55 – 14:00

Session IV: Radiomolecular Theranostics: Patients and referring physicians perspectives

14:00 – 14:10	Unmet needs for neuroendocrine patients : a global overview Josh Mailman, USA and Mark McDonnell, IRL
14:10 – 14:20	Radiomolecular Theranostics for prostate cancer patients in daily practice Matthias Heck, Germany
14:20 – 14:30	Radiomolecular Theranostics for NET patients in daily practice Christos Toumpanakis, UK
14:30 – 14:40	Key role of Multi Disciplinary Tumor Boards Marianne Pavel, Germany
PANEL 14:40 – 15:10	How to improve patient access and overall treatment outcomes? Moderated by Vikas Prasad, USA and N.N.



THURSDAY, 12 October 2023

Collaborative efforts to greater patient access to Radiomolecular Theranostics

Session VI: Recent break-throughs from Biotechs

15:10 – 15:20	Perspective by BlueEarth BRACCO Group David Gauden, UK
15:20 – 15:30	Perspective from Navigo Proteins Chris Carol Bremer, Germany
15:30 – 15:40	Perspective from ArtBio Emanuele Ostuni, Switzerland
15:40 – 15:50	Perspective from Ariceum Therapeutics Manfred Rüdiger, Germany
15:50 – 16:20	Coffee Break (served in exhibition)

Session VII: Future developments from Pharmas

16:20 – 16:30	Novartis: The M&A approach and lessons learned N. N.
16:30 – 16:40	J&J Janssen Pharmaceutica: The multiple indications route N. N.
16:40 – 16:50	Bayer: From the early days of Radium-223 to today Urs Hagermann, Germany
16:50 – 17:00	Biontech: the pre-targeting revival N. N.
18:30	Bus transfer to Munich center for ICPO Forum Dinner attendees
19:00	ICPO FORUM DINNER



FRIDAY, 13 October 2023

Radiomolecular Theranostics innovation reaching the patients in need

07:30 – 08:30 **Registration and Coffee**

08:30 – 08:35 **Welcome**

SESSION VIII: Production and delivery: Radiomolecular Theranostics at the cross-roads

08:35 – 08:45 **ITM: Meeting future demand by capacity expansion**
Steffen Schuster and Sebastian Marx, Germany

08:45 – 08:55 **Curium: Future Alpha emitters – Which Ones Will Win?**
Roy Brown, USA

08:55 – 09:05 **Eczacibasi-Monrol: Novel production facilities**
Aydin Kucuk, Turkey

09:05 – 09:15 **New technical development for high output production**
Andreas Tuerler, Switzerland

09:15 – 09:25 **Setting up a facility for the Early Supply and Commercial Supply of ²²⁵Ac**
Sven Van den Berghe, Belgium

PANEL
09:25 – 10:25 **Demand and supply: how to match in the patient's interest?**
Moderated by Andrew Scott, Australia and Oliver Buck, Germany

10:25 - 10:55 **Coffee Break** (served in exhibition)

SESSION IX: Imaging instrumentation and best quality images for dosimetry

10:55 – 11:05 **Instrumentation overview from a clinician standpoint**
Barbara Malene Fischer, Denmark

11:05 – 11:15 **Total body PETCT**
Ramsey Badawi, USA

11:15 – 11:25 **Whole body SPECTCT**
Ora Israel, Israël

PANEL
11:25 – 11:55 **Instrumentation impact on patient journey and staff considerations**
Moderated by Josh Mailman, USA and Thomas Beyer, Austria



FRIDAY, 13 October 2023

Radiomolecular Theranostics innovation reaching the patients in need

SESSION X: Ther-AI-nostics

11:55 – 12:05	AI in Theranostics tracer/target development Chris Behrenbruch, Australia
12:05 – 12:15	AI in patient workflow Antonis Kalemis, Germany
12:15 – 12:25	AI in patient diagnostic and prediction Kuangyu Shi, Switzerland
PANEL 12:25 – 12:55	Will AI help Radio Theranostics outperform amongst cancer therapies? Moderated by Thomas Beyer, Austria and Abhinav Jha, USA
12:55 – 13:55	Lunch (served in exhibition)

SESSION XI: Focus on Alpha therapies

13:55 – 14:05	Clinical status of Alpha Emitters Oliver Sartor, USA
14:05 – 14:15	The Indian perspective to Ac-225, Pb-212 and other alphas Ishita Sen, India
14:15 – 14:25	Treating prostate cancer with Ac-PSMA pre or post castration/chemio Stuart More, South Africa
PANEL 14:25 – 14:55	Alphas challenger or alternative for betas? Moderated by Cristina Müller, Switzerland and Wolfgang Weber, Germany
14:55 – 15:15	Maurits Geerlings Award for Actinium 225 Advances – Award Ceremony presented by Richard Henkelmann, Germany and Mike Sathekge, South Africa



FRIDAY, 13 October 2023

Radiomolecular Theranostics innovation reaching the patients in need

SESSION XII: FAP Oncology and Beyond

Follow up of ICPO Theranostics FAP Summit November 2022

15:15 – 15:25	The Biology of Fibroblast Activating Protein and Its Importance in Oncology Peter Choyke, USA
15:25 – 15:35	FAP derivates from tumor microenvironment to Theranostics Tadashi Watabe, Japan
15:35 – 15:45	Oncology: FAP translation and clinical trials Frederik Giesel, Germany
15:45 – 15:55	Beyond oncology: FAP in chronic diseases N.N.
PANEL 15:55 – 16:25	Has FAP already made it in clinical practice? Moderated by Elcin Zan, USA

SESSION XIII: Update on international Clinical Trials and Registries

16:25 – 16:35	Real World Data-Steps needed for making datamining more reliable and effective Vikas Prasad, USA
16:35 – 16:45	Expanding International Awareness & Education of Theranostic Trials Luke Nordquist, USA
16:45 – 16:55	NOBLE registry and online platform for the donation of radiotherapeutics Alice Viana, Belgium
16:55 – 17:05	Using AI and Natural Language Processing to improve clinical trial discovery Josh Mailman, USA
PANEL 17:05 – 17:35	Keys to successful patient access and inclusion Moderated by Richard Baum, Germany and Mark McDonnell, IRL

FINAL ROUNDTABLE

17:35 – 18:05	Outlook into Radiomolecular Theranostics globally Moderated by Vikas Prasad, USA and Oliver Sartor, USA
18:05 – 18:15	Closing of the 3rd ICPO FORUM